ArticleScientific reports2026
Comparison of health-related quality of life between radiofrequency ablation and surgery for unifocal T1N0M0 papillary thyroid carcinoma: follow-up study with up to 5 years of observation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Image-Guided Thyroid Ablation versus Surgery for T1N0M0 Papillary Thyroid Carcinoma: A Consensus-Aligned Systematic Review and Meta-Analysis.Balkan medical journal · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited information is available on impact of radiofrequency ablation (RFA) and surgery resection (SR) on the quality of life (QoL) of patients with unifocal T1N0M0 PTC. Purpose This study is to compare the QoL of RFA and SR for unifocal T1N0M0 PTC. This retrospective study was conducted in a single center. A retrospective data analysis was conducted on patients treated with RFA or SR for T1N0M0 PTC between March 2018 and March 2023. Propensity score matching (PSM) was employed to create comparable groups. The primary outcomes were the disease progression (pathologically confirmed local tumor progression, new tumors or LNM, distant metastasis identified using CT, and PTC-related mortality) and QOL. The 36-item short form health survey (SF-36) and Thyroid Cancer-Specific Quality of Life Questionnaire (THYCA-QoL) were completed by patients to evaluate their QoL scores. A total of 265 patients underwent RFA, and 325 underwent surgery. After propensity score matching, 300 patients were ultimately included, with 150 in each group. The technical success rate was 100% for both groups. According to the SF-36, PTC patients in Mainland China experienced impaired general QoL. In the two years following treatment, the QoL scores for the RFA and SR groups reached a level similar to that of the reference population. These improvements persisted 5 years post-operation. THYCA-QoL showed that the "problems with scarring" and "psychological" scale scores of patients in the RFA group were lower than in the SR group. Our study suggests that RFA provides better cosmetic, and HRQoL outcomes for T1N0M0 PTC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.